Published in Women's Health Weekly, May 20th, 2004
Under terms of an agreement signed on March 24, 2004, Barr Laboratories, Inc., granted Galen an option to acquire an exclusive license for Barr's generic version of Galen's Ovcon-35 21-day and 28-day Tablets oral contraceptive. Galen has 45 days to exercise its option from the date of FDA approval.
If Galen exercises its option, it will be granted a 5-year exclusive license to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly